Physician profile
Nabil Azer Phillips
NPI 1043276405
$2,713.52
in general payments reported to CMS, 2019-2025
20 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $473 · 2022: $506 · 2023: $240 · 2024: $666 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.11 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $382.22 | 2019-2024 | Ultomiris |
| Exelixis INC. | $273.41 | 2019-2024 | Cabometyx |
| Eisai INC. | $245.14 | 2024 | |
| Astellas Pharma US INC | $238.84 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $210.44 | 2022 | |
| Seagen INC. | $199.27 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $186.67 | 2019-2020 | |
| Genentech USA, INC. | $150.00 | 2019 | |
| Merck Sharp & Dohme LLC | $139.38 | 2024-2025 | Keytruda |
| Blueprint Medicines Corporation | $131.83 | 2024 | Ayvakit |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Jazz Pharmaceuticals INC. | $124.99 | 2022 | |
| Abbvie INC. | $59.26 | 2020 | |
| Pfizer INC. | $56.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.97 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.83 | 2019 | |
| Coherus Oncology, INC. | $26.06 | 2022 | |
| Acrotech Biopharma INC. | $23.68 | 2024 | Beleodaq |
| Pharmacyclics LLC, An Abbvie Company | $22.87 | 2022 | |
| Incyte Corporation | $17.69 | 2024 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.